AI in Diagnostics market is expected to reach USD 8,081.97 million by 2032 | DelveInsight

DelveInsight's "Artificial Intelligence (AI) in Diagnostics Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Diagnostics companies actively working in the market.

DelveInsight Analysis: The AI in Diagnostics market, valued at USD 1,623.20 million in 2024, is projected to expand at a compound annual growth rate (CAGR) of 22.31% from 2025 to 2032, reaching an estimated USD 8,081.97 million by 2032.

According to DelveInsight's analysis, The increasing incidence of infectious and chronic diseases is fueling the need for early and accurate diagnosis, where Artificial Intelligence plays a crucial role by improving detection and enabling quicker clinical decisions. At the same time, the widespread adoption of digital health and imaging technologies is creating a robust platform for incorporating AI solutions into current healthcare systems, enhancing both efficiency and accuracy. Moreover, the surge in product development efforts by leading Artificial Intelligence in Diagnostics companies worldwide, supported by advancements in machine learning and favorable regulatory frameworks, is broadening access to AI-driven diagnostic tools. Collectively, these factors are anticipated to drive substantial growth in the global Artificial Intelligence in Diagnostics market, facilitating more precise, timely, and scalable healthcare solutions during the 2025 to 2032 forecast period.

To know more about why North America is leading the market growth in the Artificial Intelligence (AI) in Diagnostics market, get a snapshot of the report Artificial Intelligence (AI) in Diagnostics Market Trends - https://www.delveinsight.com/sample-request/ai-in-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Artificial Intelligence (AI) in Diagnostics Overview
Artificial Intelligence (AI) in Diagnostics, also known as ear tubes or grommets, are small cylindrical devices inserted into the eardrum to allow air to enter the middle ear and prevent fluid buildup. They are commonly used to treat recurrent ear infections (otitis media) or persistent middle ear fluid (effusion) in children and adults. Artificial Intelligence (AI) in Diagnostics help improve hearing, reduce the risk of infection, and relieve pressure or pain caused by fluid accumulation. The procedure to insert these tubes is called myringotomy and is typically quick and minimally invasive. The tubes often fall out on their own within 6 to 18 months.

Artificial Intelligence (AI) in Diagnostics Market Insights
Geographically, North America is expected to hold the largest share of the AI in Diagnostics market in 2024. This leading position is driven by several critical factors, such as the growing incidence of chronic and infectious diseases, widespread adoption of imaging technologies, strong research and development (R&D) activities, a well-developed healthcare infrastructure, and a supportive regulatory framework that facilitates product approvals and market entry.

To read more about the latest highlights related to Artificial Intelligence (AI) in Diagnostics, get a snapshot of the key highlights entailed in the Artificial Intelligence (AI) in Diagnostics
https://www.delveinsight.com/report-store/ai-in-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Recent Developments in the Artificial Intelligence (AI) in Diagnostics Market Report
• In April 2025, Roche has revealed that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its VENTANA® TROP2 (EPR20043) RxDx Device. This represents the first time a computational pathology companion diagnostic (CDx) device has received this designation.
• In April 2025, Avant Technologies, Inc., along with its joint venture partner Ainnova Tech, Inc., announced that the U.S. Food and Drug Administration (FDA) is currently reviewing their submission package for a pre-submission meeting focused on Avant's VisionAI platform. This AI-driven technology is designed to transform the early detection of diseases through advanced artificial intelligence solutions.
• In April 2025, Proprio announced that its Paradigm AI surgical guidance platform has received FDA 510(k) clearance to incorporate intraoperative measurements, marking the first time surgeons can access real-time, 3D, dynamic, and segmental anatomical visualization and measurement during procedures.
• In September 2024, Ibex Medical Analytics (Ibex), a leading company in AI-based cancer diagnostics, unveiled the latest enhancements to its Ibex-AI platform. Developed in partnership with experienced pathologists across the globe who regularly utilize the platform in clinical practice, these updates reflect Ibex's dedication to delivering advanced diagnostic solutions designed to support healthcare professionals directly involved in patient care.
• In October 2023, Lucida Medical Ltd announced that its AI-driven prostate cancer detection software, Prostate IntelligenceTM (PiTM), has been awarded Class IIb CE certification. Utilizing advanced AI technology, PiTM analyzes MRI scans and integrates smoothly into the radiologist's workflow.
• In March 2023, Qritive has introduced its newest AI-powered solution, QAi Prostate, developed to enhance prostate cancer diagnosis. The platform uses advanced machine learning algorithms to accurately analyze whole slide images of prostate core needle biopsies.
• Thus, owing to such developments in the market, rapid growth will be observed in the Artificial Intelligence (AI) in Diagnostics market during the forecast period

Key Players in the Artificial Intelligence (AI) in Diagnostics Market
Some of the key market players operating in the Artificial Intelligence (AI) in Diagnostics market include- Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and others.

Which MedTech key players in the Artificial Intelligence (AI) in Diagnostics market are set to emerge as the trendsetter explore @ Key Artificial Intelligence (AI) in Diagnostics Companies
https://www.delveinsight.com/sample-request/ai-in-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Analysis on the Artificial Intelligence (AI) in Diagnostics Market Landscape
As reported by the British Heart Foundation (2025), approximately 640 million people worldwide are living with heart and circulatory diseases. These conditions require early and accurate diagnosis, as timely detection significantly improves patient outcomes and reduces mortality. Artificial Intelligence (AI) tools are increasingly being adopted in diagnostic workflows to analyze medical images such as CT scans, MRIs, and echocardiograms, offering greater precision and efficiency compared to conventional methods, thereby driving growth in the Artificial Intelligence in Diagnostics market.
Moreover, the expanding use of digital health solutions and advanced imaging technologies is further propelling the AI diagnostics market by enhancing the speed, accuracy, and accessibility of diagnostic processes. AI-powered algorithms can effectively interpret complex imaging data, facilitating early diagnosis in key areas such as oncology, cardiology, and pulmonology. For example, in December 2024, GE HealthCare unveiled its Sonic DL AI MRI algorithm at the RSNA 2024 conference. This innovation accelerates MRI scans by up to 86% while improving image clarity for brain, spine, orthopedic, and body imaging applications. Collectively, these factors are anticipated to drive significant growth in the global Artificial Intelligence in Diagnostics market.

Scope of the Artificial Intelligence (AI) in Diagnostics Market Report
• Coverage: Global
• Study Period: 2022-2032
• Artificial Intelligence (AI) in Diagnostics Market Segmentation By Product Type: Hardware/software, and Services
• Artificial Intelligence (AI) in Diagnostics Market Segmentation By Application Type: Infectious Disease Diagnostics, Radiology, Oncology, Cardiology, and others
• Artificial Intelligence (AI) in Diagnostics Market Segmentation By Technology Type: (Machine Learning, Natural Language Processing, and Others
• Artificial Intelligence (AI) in Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key Artificial Intelligence (AI) in Diagnostics Companies: Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and others
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Interested in knowing how the Artificial Intelligence (AI) in Diagnostics market will grow by 2032? Click to get a snapshot of the Artificial Intelligence (AI) in Diagnostics Market Analysis
https://www.delveinsight.com/sample-request/ai-in-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.